We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+5.61%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$253M
AUM Growth
+$63.7M
(+34%)
Cap. Flow
+$59.7M
Cap. Flow
% of AUM
23.62%
Top 10 Holdings %
Top 10 Hldgs %
44.38%
Holding
92
New
44
Increased
11
Reduced
15
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$13.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$12.1M |
| 3 |
Gilead Sciences
GILD
|
+$10.4M |
| 4 |
Takeda Pharmaceutical
TAK
|
+$8.8M |
| 5 |
Icon
ICLR
|
+$8.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$14.6M |
| 2 |
CELG
Celgene Corp
CELG
|
+$10.8M |
| 3 |
CVS Health
CVS
|
+$8.43M |
| 4 |
SHPG
Shire pic
SHPG
|
+$8.02M |
| 5 |
DaVita
DVA
|
+$7.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.31% |
| 2 | Technology | 10.37% |
| 3 | Industrials | 2.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Thermo Fisher Scientific
TMO
$213B
| $2.87M | 1.14% |
+10,500
| New | +$2.61M |
|
27
Ocular Therapeutix
OCUL
$1.79B
| $2.84M | 1.12% |
716,124
+483,397
| +208% | +$1.94M |
|
|
LMNX
28
DELISTED
Luminex Corp
LMNX
| $2.79M | 1.1% |
+121,017
| New | +$3.04M |
|
|
NTGN
29
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| $2.75M | 1.09% |
+425,291
| New | +$2.23M |
|
30
Liquidia Corp
LQDA
$7.48B
| $2.68M | 1.06% |
235,329
+196,190
| +501% | +$3.14M |
|
|
AGN
31
DELISTED
Allergan plc
AGN
| $2.67M | 1.06% |
18,263
-100,808
| -85% | -$14.6M |
|
32
Elevance Health
ELV
$81.5B
| $2.61M | 1.03% |
+9,084
| New | +$2.63M |
|
33
Bausch Health
BHC
$2.58B
| $2.58M | 1.02% |
104,344
-59,564
| -36% | -$1.42M |
|
34
Vericel Corp
VCEL
$2.35B
| $2.16M | 0.85% |
+123,111
| New | +$2.25M |
|
|
XENT
35
DELISTED
Intersect ENT, Inc
XENT
| $2.11M | 0.83% |
+65,557
| New | +$2.03M |
|
36
Krystal Biotech
KRYS
$10.1B
| $2.01M | 0.8% |
61,155
+48,655
| +389% | +$1.15M |
|
|
SIOX
37
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $1.93M | 0.76% |
+181,664
| New | +$1.81M |
|
38
Abbott
ABT
$183B
| $1.92M | 0.76% |
+23,966
| New | +$1.78M |
|
39
Align Technology
ALGN
$12.1B
| $1.86M | 0.74% |
+6,557
| New | +$1.56M |
|
|
MRNS
40
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.83M | 0.72% |
+109,325
| New | +$1.57M |
|
41
Viking Therapeutics
VKTX
$3.7B
| $1.77M | 0.7% |
178,448
+124,982
| +234% | +$1.05M |
|
|
OXFD
42
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $1.77M | 0.7% |
102,593
-358,641
| -78% | -$5.68M |
|
43
AbbVie
ABBV
$443B
| $1.75M | 0.69% |
+21,674
| New | +$1.77M |
|
44
Sarepta Therapeutics
SRPT
$1.57B
| $1.71M | 0.68% |
14,364
-7,251
| -34% | -$932K |
|
45
Dentsply Sirona
XRAY
$2.68B
| $1.44M | 0.57% |
28,988
-89,436
| -76% | -$3.94M |
|
|
TVTY
46
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $1.37M | 0.54% |
+77,929
| New | +$1.66M |
|
47
Agilent Technologies
A
$39.1B
| $1.01M | 0.4% |
+12,583
| New | +$955K |
|
|
RVLP
48
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
| $1.01M | 0.4% |
279,561
+47,513
| +20% | +$350K |
|
49
Molina Healthcare
MOH
$10.2B
| $828K | 0.33% |
+5,830
| New | +$788K |
|
|
SIEN
50
DELISTED
Sientra, Inc.
SIEN
| $758K | 0.3% |
+8,837
| New | +$989K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Endurant Capital Management held 92 positions worth $253M, up 34% from $189M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Endurant Capital Management deployed $59.7M of net new capital in Q1 2019, opening 44 new positions and adding to 11 existing holdings. Its largest new stake was VOCERA COMMUNICATIONS, INC.: 390,887 shares worth $12.4M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 91% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Allergan plc, an estimated $14.6M trimmed.
- Endurant Capital Management's largest Q1 2019 buy was VOCERA COMMUNICATIONS, INC.: 390,887 shares worth $12.4M.
- Endurant Capital Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.1M increase.
- Endurant Capital Management's biggest Q1 2019 reduction was Allergan plc, cutting an estimated $14.6M.
- Endurant Capital Management fully exited Celgene Corp in Q1 2019, selling an estimated $10.8M.
- Endurant Capital Management's ten largest holdings make up 44% of its $253M portfolio in Q1 2019.
- Endurant Capital Management opened 44 new positions and closed 22 in Q1 2019.
- Endurant Capital Management's portfolio value rose 34% quarter-over-quarter to $253M.
Based on Endurant Capital Management's 13F filing for Q1 2019, filed 15 May 2019.